Verdiva Bio Limited has dosed the first participant in a Phase 1 study of VRB-103, an investigational selective oral amylin peptide analog being developed for people with overweight or obesity. The first-in-human programme will assess VRB-103 as a monotherapy and in combination with Verdiva Bio’s once-weekly oral GLP-1 candidate VRB-101, also known as oral ecnoglutide.
The July 30, 2026 announcement moves Verdiva Bio’s second oral peptide programme into clinical development and creates an early test of whether the company’s oral delivery platform can support weekly dosing across two complementary obesity mechanisms. Verdiva Bio anticipates reporting initial Phase 1 data by the end of 2026, although the registered study is considerably broader and is not scheduled to reach primary completion until March 2028.
That timing distinction matters. A late-2026 disclosure would probably cover early safety, tolerability and pharmacokinetic observations from the initial dose-escalation cohorts rather than provide a complete assessment of the full programme. It would not establish that VRB-103 causes clinically meaningful weight loss, improves long-term weight maintenance or offers better tolerability than existing obesity medicines.
The strategic appeal is nevertheless clear. Most advanced peptide obesity treatments remain injectable, while oral peptide products generally require more frequent administration. A genuinely once-weekly oral amylin medicine could therefore occupy a differentiated position, provided Verdiva Bio can demonstrate reliable drug exposure, an acceptable safety profile and sufficient biological activity in humans.
What will the VRB-103 Phase 1 study actually measure before efficacy can be considered?
The registered Phase 1 study, identified as NCT07628127, is a randomised, placebo-controlled and masked first-in-human trial expected to enrol approximately 336 participants. It includes people with elevated body mass index who are otherwise considered healthy, rather than a broad population with the cardiovascular, metabolic and other complications commonly associated with obesity.
The programme contains a single-ascending-dose component and two multiple-ascending-dose components. Participants may receive VRB-103 alone, VRB-101 alone, a combination of the two investigational medicines or placebo, depending on the assigned cohort. The study design also includes the assessment of different dosing frequencies in certain cohorts before moving into weekly administration.
The primary objectives concern safety and tolerability. Investigators will monitor treatment-emergent adverse events, serious adverse events, adverse events of special interest, laboratory findings and electrocardiogram parameters. The protocol also includes changes in Columbia-Suicide Severity Rating Scale and Patient Health Questionnaire-9 assessments, with follow-up extending to Day 29 in the single-dose section, Week 10 in one multiple-dose section and Week 20 in the longer multiple-dose section.
Secondary measures focus on pharmacokinetics, including plasma concentrations, maximum observed concentration, time to maximum concentration, total exposure, trough concentrations and half-life. These measurements will help determine whether oral VRB-103 can maintain exposure compatible with weekly administration and whether co-administration with VRB-101 materially changes the pharmacokinetic behaviour of either candidate.
Body-weight changes may eventually provide exploratory information during the longer cohorts, but the study is not a confirmatory efficacy trial. The most meaningful early result would be evidence that VRB-103 reaches predictable exposure levels while remaining sufficiently tolerable to justify longer and larger studies in representative obesity populations.
Why is Verdiva Bio developing an amylin medicine rather than another standalone GLP-1 therapy?
Amylin is a peptide hormone released with insulin after food intake. It participates in appetite regulation, gastric emptying and glucagon control through receptors formed from the calcitonin receptor and receptor activity-modifying proteins.
Amylin-based medicines are attracting increasing industry interest because they may provide weight-management effects through a mechanism that is distinct from, but potentially complementary to, GLP-1 receptor agonism. The approach could support standalone treatment for certain patients or combination regimens intended to produce greater weight reduction than either mechanism can deliver alone.
Verdiva Bio has designed VRB-103 to favour human amylin receptors over the calcitonin receptor. The company believes this selectivity could help separate desired amylin activity from receptor effects that may influence efficacy or tolerability. That remains a therapeutic hypothesis rather than an established clinical advantage.
At the American Diabetes Association’s 2026 Scientific Sessions, Verdiva Bio reported that VRB-103 showed high potency across human amylin receptor subtypes in laboratory testing and greater receptor selectivity than the comparator molecules evaluated in its assays. The company also reported an oral pharmacokinetic profile that it considered compatible with further development.
Those findings supported the transition into Phase 1, but receptor activity in cell-based systems cannot predict the eventual magnitude of weight loss, gastrointestinal tolerability or treatment discontinuation in humans. Comparisons with cagrilintide and eloralintide are also based on preclinical assays rather than head-to-head clinical trials, so they cannot establish superior clinical performance.
Could receptor selectivity translate into better tolerability than existing obesity medicines?
Verdiva Bio is positioning VRB-103 partly around the possibility of a more favourable tolerability profile for people who cannot tolerate or do not respond adequately to GLP-1 therapy. The company has also described amylin agonism as a potential non-incretin alternative for the induction and maintenance of weight loss.
That positioning addresses a genuine development opportunity, but the Phase 1 trial must first establish what adverse events emerge as exposure increases. Appetite-regulating peptides can produce gastrointestinal symptoms, and tolerability may depend on dose, titration, treatment duration and whether VRB-103 is administered alone or with a GLP-1 medicine.
Combination development creates a particularly important test. Pairing two mechanisms may strengthen weight-loss activity, but it could also increase nausea, vomiting or treatment discontinuations if the dose ratios and titration schedules are not carefully calibrated. The study’s evaluation of multiple combination ratios should therefore be viewed as dose-finding work rather than evidence that a fixed oral combination is ready for later-stage development.
The longer multiple-dose cohorts will provide more useful information than the initial single-dose portion because many tolerability problems emerge during repeated treatment or dose escalation. Even then, a Phase 1 population of otherwise healthy participants with elevated body mass index may not reveal the full safety and adherence profile that would occur in people with diabetes, cardiovascular disease, liver disease or extensive concomitant medication use.
How important is the oral delivery platform to VRB-103’s weekly dosing proposition?
Large peptide molecules are difficult to administer orally because the gastrointestinal environment can degrade them and restrict absorption. Verdiva Bio is using its proprietary oral absorption enhancer, known as T2026, to support delivery of VRB-103 and VRB-101.
The company has described the platform as clinically validated based primarily on experience with VRB-101. Verdiva Bio reported that Phase 1 pharmacokinetic findings supported the feasibility of once-weekly oral ecnoglutide, while its Phase 2b EVOLVE-2 study is now testing several doses and titration strategies over 20 weeks.
EVOLVE-2 completed enrolment of 206 participants across 22 United States sites, with topline results expected by the end of 2026. Its primary endpoint is the mean percentage change in body weight from baseline, giving Verdiva Bio its first substantial opportunity to determine whether the exposure achieved with weekly oral VRB-101 translates into clinically relevant weight reduction.
VRB-103 will need to demonstrate similar delivery consistency independently. Pharmacokinetic variability between participants, sensitivity to meals, the amount of absorption enhancer required and the reproducibility of exposure across repeated doses could all influence whether weekly oral administration remains practical.
The oral formulation must also compete with increasingly convenient injectable devices and established oral GLP-1 products. An oral tablet is not automatically simpler if it carries restrictive fasting instructions, produces variable absorption or requires a peptide dose that complicates manufacturing economics. The Phase 1 programme should begin clarifying those questions, although many commercial manufacturing details have not been publicly disclosed.
How does VRB-103 compare with the rapidly advancing amylin obesity pipeline?
Verdiva Bio describes VRB-103 as the first known once-weekly oral amylin analog to enter clinical development. That claim appears directionally consistent with the visible competitive landscape, where the most advanced selective amylin programmes use subcutaneous administration, although first-in-class descriptions can change as private and undisclosed programmes emerge.
Eli Lilly and Company has moved the once-weekly injectable amylin agonist eloralintide into a broad Phase 3 programme. Studies are evaluating the candidate in people with obesity with and without type 2 diabetes, in people remaining above treatment goals while receiving incretin therapy, and in obesity-associated conditions including obstructive sleep apnoea and knee osteoarthritis.
Zealand Pharma and Roche are preparing to advance the once-weekly injectable amylin analog petrelintide into Phase 3 development during the second half of 2026. Zealand Pharma is also developing combinations intended to pair petrelintide with incretin-based medicines for patients requiring additional weight reduction or glycaemic control.
Novo Nordisk is pursuing amylin through several approaches, including cagrilintide combinations and zenagamtide, previously known as amycretin. Zenagamtide activates both GLP-1 and amylin receptors and is being investigated in separate oral and subcutaneous programmes, with Phase 3 development planned after positive Phase 2 findings.
VRB-103 is therefore earlier than several major competitors and cannot yet compete on proven efficacy. Its differentiation rests instead on route and frequency of administration, receptor selectivity and the possibility of combining two weekly oral peptides. That proposition will become meaningful only after Verdiva Bio demonstrates human exposure and tolerability and then produces controlled evidence of sustained weight reduction.
Why could the VRB-101 combination become more valuable than VRB-103 monotherapy?
The combination strategy may ultimately be the most commercially important part of the programme. GLP-1 and amylin act through different but overlapping appetite and metabolic pathways, creating a rationale for combining the mechanisms to increase weight reduction or broaden treatment options.
Verdiva Bio’s approach differs from programmes that place two activities in a single injectable molecule. The company is developing VRB-101 and VRB-103 as separate oral peptides, potentially allowing their doses to be adjusted independently during development. That flexibility may help researchers identify a ratio that balances efficacy and tolerability.
It also introduces formulation and adherence questions. Co-administering two tablets is not equivalent to producing a stable single-tablet combination, and Verdiva Bio has not yet demonstrated that the candidates can be combined commercially without changing absorption, exposure or manufacturing complexity. The Phase 1 study is designed to address the initial clinical interaction rather than resolve the final product format.
The timing of the VRB-101 and VRB-103 readouts could nevertheless give Verdiva Bio an unusually informative dataset. EVOLVE-2 may show whether weekly oral ecnoglutide produces competitive weight reduction, while the early VRB-103 results may indicate whether the same delivery platform can support an amylin peptide. Positive findings across both programmes would strengthen the rationale for combination development, although each candidate would still require extensive dose-ranging and longer-duration testing.
What must Verdiva Bio demonstrate before VRB-103 can become a credible obesity medicine?
Verdiva Bio entered 2025 with $411 million from an oversubscribed Series A financing led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures and LYFE Capital. The financing gave the private biotechnology company substantial resources to advance the portfolio it licensed from Sciwind Biosciences outside Greater China and South Korea.
Capital and a differentiated formulation strategy can accelerate development, but they do not remove the scientific risks facing oral peptide medicines. VRB-103 must demonstrate acceptable tolerability across escalating doses, consistent exposure between participants, a half-life compatible with weekly use and no adverse interaction with VRB-101.
Later studies will need to establish dose-dependent weight reduction, durability, effects on lean and fat mass, discontinuation rates and performance in populations with obesity-related complications. Verdiva Bio will also need to show that any tolerability advantage is clinically meaningful rather than inferred from receptor selectivity or preclinical experiments.
The end-of-2026 update will consequently be an early filter rather than a decisive obesity readout. Evidence of predictable weekly exposure and manageable repeated-dose tolerability would support continued development. Weak absorption, substantial variability or difficulty combining VRB-103 with oral ecnoglutide would challenge the central premise of Verdiva Bio’s modular oral obesity platform.
For now, the start of the study establishes that VRB-103 has crossed from laboratory development into human testing. The harder question is whether a selective amylin peptide can retain sufficient biological activity after oral delivery to offer the convenience of a weekly tablet without sacrificing tolerability, consistency or meaningful weight-management efficacy.
